Definitive Healthcare Corp. — 2021 Form 10-K
Business context and reporting period. This is the company’s annual report for the fiscal year ended December 31, 2021, not a standalone fourth-quarter report. Definitive Healthcare sells subscription access to a cloud-based healthcare commercial intelligence platform; subscriptions represented 99% of 2021 revenue. The company completed its IPO in September 2021 and a follow-on offering in November, becoming a public holding company that consolidates Definitive OpCo.
Key financial metrics
| Metric | 2021 | 2020 |
|---|---|---|
| Revenue | $166.2 million | $118.3 million |
| GAAP gross profit / margin | $125.5 million / 75.5% | $87.8 million / 74.2% |
| Adjusted gross profit / margin | $146.0 million / 88% | $107.1 million / 91% |
| Operating loss | $25.0 million | $14.4 million |
| Net loss | $61.3 million | $51.2 million |
| Adjusted EBITDA / margin | $56.0 million / 34% | $53.5 million / 45% |
| Cash from operating activities | $25.2 million | $23.2 million |
| Cash used in investing activities | $46.7 million | $23.9 million |
| Cash from financing activities | $384.4 million | $16.7 million |
Revenue increased 40.4%, primarily from expansion among existing customers and new customer additions, with a smaller contribution from Monocl. Net loss widened by $10.1 million; operating expenses rose 47% as the company hired, invested in growth, prepared for public-company reporting, and incurred higher equity compensation. Adjusted EBITDA increased modestly, while its margin declined 11 percentage points. Adjusted measures exclude specified costs and are not GAAP measures.
At year-end, cash and cash equivalents were $387.5 million, with $75.0 million available on the revolving facility and no revolver borrowings. Term-loan principal was $273.3 million, at a 2.47% effective interest rate; the facility matures in September 2026 and includes a maximum-leverage covenant. The company reported $250.5 million of remaining performance obligations, including $155.1 million expected to be recognized within 12 months. Total assets included $1.26 billion of goodwill and $352.5 million of net intangible assets.
Material changes and unusual items
- 2021 revenue grew 40.4% year over year. Customer net dollar retention was 120% for enterprise customers and 111% for customers above $17,500 ARR, versus 124% and 108%, respectively, in 2020.
- IPO and follow-on offerings generated $835.0 million of net proceeds before related share and LLC-unit repurchases. The company used IPO proceeds in part to repay its prior credit facility; financing cash flow also reflects new borrowing, debt repayment, and offering-related transactions.
- The September refinancing reduced the stated effective borrowing rate versus the prior facility, but resulted in a $9.9 million loss on debt extinguishment. Management expected interest expense to be lower in 2022 following refinancing.
- In December 2021, the company invested $40.0 million for 35% of Analytical Wizards and an option to buy the remaining interest. On February 18, 2022, it acquired the remaining 65% for $65.0 million, subject to working-capital adjustments; purchase accounting was incomplete when the filing was issued.
- Reported consolidated net loss was $61.3 million; net loss attributable to Definitive Healthcare Corp. was $17.7 million, reflecting the post-reorganization ownership structure. Reported basic and diluted loss per share of $0.19 covers only the period after the IPO and reorganization.
Outlook, risks and contingencies
The filing provides no numerical revenue or earnings guidance. Management described growth plans centered on customer acquisition, expanding existing accounts, continued platform investment, and selective acquisitions. It anticipated continued investment in product development; sales and marketing expense as a percentage of revenue could remain consistent in 2022, while public-company costs were expected to increase general and administrative expense as a percentage of revenue in 2022. Management said operating cash flow, cash on hand, and credit availability were expected to meet current short- and long-term needs, while noting that future liquidity depends on operating performance and financing availability.
- Key business risks include dependence on subscription demand and external data providers, competitive and pricing pressure, customer renewal and expansion, data quality, cybersecurity, and evolving privacy and healthcare regulation.
- The company cited COVID-19 as having slowed bookings and growth early in the pandemic, although demand had recovered; longer-term effects remained uncertain. It also identified uncertainty from Russia’s invasion of Ukraine and related macroeconomic conditions.
- The credit facility is secured by substantially all assets of specified borrowers and guarantors, restricts certain activities, and requires covenant compliance. Variable-rate debt exposes the company to higher interest expense if rates rise.
- The Tax Receivable Agreement requires payment to specified holders of 85% of certain realized or deemed tax benefits. The year-end liability was $153.5 million; the filing says payments may be substantial and may accelerate in certain change-of-control or termination circumstances.
- Monocl contingent consideration was valued at $7.5 million at year-end and was classified as current, with a payout expected in the first quarter of 2022. Management said ordinary-course legal matters were not expected to have a material adverse effect.
Important facts for investors to verify
- Whether revenue growth and retention remain strong, especially given the year-over-year decline in Adjusted EBITDA margin and adjusted gross margin.
- Cash conversion, deferred revenue and cRPO trends, and how much operating cash flow remains after capital spending and acquisition investment.
- Debt covenant headroom, variable-rate exposure, scheduled repayments, and the effect of the Analytical Wizards acquisition on liquidity and leverage.
- The assumptions supporting goodwill and intangible-asset values, the Analytical Wizards purchase accounting, and the size and timing of Tax Receivable Agreement payments.
- Customer and provider-data access, data accuracy, privacy compliance, and cybersecurity controls. The company reported effective disclosure controls, but did not include management’s internal-control-over-financial-reporting assessment or an auditor attestation under the newly public company transition rules.